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SUMMARY OF RESULTS
This thesis was divided into two parts. Part 1 focused on a lower middle-income 
country (LMIC) in Asia, namely Indonesia, and the long-term cardiovascular disease 
(CVD) burden, as well as the country-specific challenges in prescribing guideline-
recommended medications for the secondary prevention of CVD. Part 2 focused 
on the high-income country of the Netherlands and the challenges in relation to 
adherence to and the effects of statin therapy, especially in the primary prevention of 
CVD in the Netherlands.
We estimated the long-term risk (> 10 years) of CVD in Asian populations using a 
systematic review and meta-analysis of cohort studies (Part 1, Chapter 2). Most
studies were from East-Asian regions during a period of time when the prescription 
of preventive cardiovascular (CV) medications was not strongly advised by clinical 
guidelines. We observed a high risk of a more than 1 in 5 chance of dying from CVD 
over a mean risk period of 20 years among Asians (6.35%). Of note, in contrast with 
most high-income countries, the average long-term incidence rate of any stroke was 
higher than that of fatal/non-fatal coronary events (3.14 per 1,000 person-years [95% 
CI 2.12–4.16] vs. 1.51 [0.84–2.18]). We learned from the meta-analysis that only a 
few risk factors for death due to CVD were statistically significantly related. Male sex, 
older age (≥ 60 or ≥ 65 years old) and current smoking were risk factors for fatal 
CVD. Importantly, in several studies, the long-term risk factors for fatal stroke were 
different from those associated with long-term risk of fatal coronary artery disease 
(CAD). While a higher non-high-density lipoprotein cholesterol level (non-HDL-c = 
HDL-c subtracted from total cholesterol level) was associated more with fatal CAD, 
hypertension was associated more with fatal stroke. 
In a retrospective cohort study of Indonesian patients with an ST-elevation myocardial 
infarction (STEMI), 42% were not treated with acute primary percutaneous coronary 
intervention (pPCI), as is strongly advised by international and national clinical 
guidelines (Chapter 3). However, 75% of these patients were late hospital-admitters, 
who are generally underrepresented in clinical trials. Therefore, the benefits of using 
pPCI and secondary-preventive CV medications in this subset of patients with a 
high risk of in-hospital mortality were unclear. In our cohort study, we found that 




CV medications on hospital admission. After adjustment for potential confounders, 
the prescription of guideline-recommended medications (dual antiplatelet therapy, 
anticoagulants, and statins) halved the risk of in-hospital mortality. It was apparent that 
the acuteness and severity of the STEMI correlated positively with guideline non-adherence.
One-third of patients with STEMI who were admitted to hospital did not receive 
all five guideline-recommended medications (antiplatelet, clopidogrel, beta-blockers, 
angiotensin-converting enzyme inhibitors [ACIs]/angiotensin receptor blockers 
[ARBs], and statins) at discharge (Chapter 4). The predictors of receiving less
than five medications were: the presence of non-anterior MI; age > 65 years; not 
being treated with acute reperfusion therapy; having a family history of CAD; 
and having a thrombolysis in myocardial infarction (TIMI) score ≥ 4. Despite the 
presence of different predictors for separate drug classes, not being treated with 
acute reperfusion therapy was the most common predictor of not receiving most of 
the recommended secondary preventive medications. Our finding therefore suggests 
that prescribers may have different opinions on the benefit-risk of using guideline-
recommended medications for different patient groups, and a more personalized 
approach is required. 
We also conducted a small-scale qualitative study to gain insight into the prescribing 
of statins in primary care in Indonesia from the physicians’ perspective (Chapter 5). 
Key factors influencing the decision to prescribe statins at the micro level were several 
patient characteristics, especially a high level of total cholesterol (TC), combined with 
other characteristics such as clinical symptoms, comorbidities and other risk factors. 
At the macro level, the physicians appeared to be aware of the relevant guidelines, 
but there was uncertainty in how to take into account the level of TC in combination 
with other CV risk factors, such as diabetes and hypertension, as recommended by 
the guidelines. The recently introduced National Health Insurance System (NHIS), 
the Jaminan Kesehatan Nasional (JKN), appeared to facilitate the prescription of 
statins, although information that is more clinical should be integrated into the 
system’s platform to support a personalized medicine approach and guideline-based 
prescribing.
Part 2 presented studies using the PharmLines Initiative, a database linking the 
Netherlands Lifelines Cohort Study and the IADB.nl community prescription 
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database (Chapter 6), finding that there are potential disparities between the sexes
in CVD prevention. Among all first-time statin users, we found that statin therapy 
was significantly more effective in increasing HDL-c levels in women than in men, 
irrespective of their previous history of CVD. The proportion of men and women 
who achieved the LDL-c treatment goal recommended by the Dutch guidelines (≤ 
2.5 mmol/L) was just below 40% without statistically significant differences between 
the sexes. The level of adherence to statin therapy in both subgroups (of men and 
women) was low. Using the same database, we found that the level of adherence 
was similarly associated with LDL-c response in first-time statin users of a standard-
dose and a low-dose group (Chapter 7). However, the same level of adherence
was associated with a significantly slower rate of reduction of LDL-c among male 
participants than among female participants. In the standard-dose group, adherence 
was associated with a reduction of LDL-c response at follow-up at a significantly 
faster rate in women than in men. In the low-dose group, there was no significant 
difference between the sexes in the rate of LDL-c reduction.
STRENGTHS AND LIMITATIONS
Our literature review was based on a comprehensive search strategy aiming to include 
studies from all Asian countries and a selection of cohort studies with participants 
free from CVD at baseline. This enabled the estimation of absolute risks, especially 
the burden of CVD in the general population, to inform strategy for the primary 
prevention of CVD (Part 1, Chapter 1). 
Published studies of high-risk Indonesian patients focusing on the prevalence of use 
of preventive CV medications, their effectiveness and predictors of the suboptimal 
utilization are very limited to almost non-existent.1–4 We are the first to provide 
more solid evidence on their use, as well as the challenges (Part 1, Chapters 2 
and 3) and their effectiveness (Part 1, Chapter 2). One important strength was
that we examined patients in a real-world setting, which is different to a clinical trial, 
where recommendations in guidelines are commonly used as the basis for treatment. 
We used the Jakarta Acute Coronary Syndrome (JAC) Registry, which has been set up 
since 2007.5 The JAC Registry prospectively collected and managed data on patients with 




Harapan Kita (NCCHK), which is the largest tertiary cardiac referral hospital in Jakarta, the 
capital of Indonesia. The data were collected using a standardized form and verified regularly.6 
The hospital is JCI (Joint Committee International) accredited. Consequently, the risk of 
information bias is low, the results of the studies were more representative of clinical 
practice, and they more accurately reflect the clinical event rates. Furthermore, our 
qualitative study is the first to explore physicians’ perspectives on how they come 
to the decision to prescribe a specific preventive CV medication in a clinical practice 
setting in Indonesia (Part 1, Chapter 4). 
For our studies on the effect of statin therapy on lipid parameters in a Dutch 
population, we used the PharmLines Initiative database, which linked IADB.nl and the 
Lifelines Cohort databases. The data in IADB and the Lifelines Cohort were collected 
prospectively. IADB data has been proven to be valid and representative of the overall 
population of the Netherlands,7 and the Lifelines adult population is representative 
of the adult population in the northern Netherlands. The recruitment strategy means 
that the selection bias is low and that the results obtained from Lifelines can be applied 
to the Dutch general population (Part 2, Chapters 5 and 6).8 The amount of
data on demographic, clinical, physical and medication characteristics for each patient 
is large (more than 4000 variables per person), which makes such databases suitable 
for accurate causal and predictive studies. 
Nevertheless, several limitations need to be addressed. In the systematic review, 
most of the indexed articles eligible for analysis were in English as the main language. 
Due to a relatively small number of articles included, we were not able to detect 
the potential for publication bias. It is possible that we may have overlooked some 
information from unpublished articles in other languages, including Asian countries 
such as Indonesia, although the influence on the observed associations is unclear. 
We also only used a single registry from a tertiary cardiac-referral academic hospital 
in the largest urban area in Indonesia. Patients referred to this type of hospital may 
have different characteristics than those referred to secondary referral hospitals, 
non-pPCI hospitals, non-academic hospitals, or other types of hospitals in other 
urban areas of a smaller size and population than Jakarta. In a study with an extended 
population beyond the JAC Registry it was reported that the proportion of non-
reperfused STEMI patients with a TIMI score ≥ 4 and onset of MI ≥ 12 hours were 
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significantly higher at pPCI centres than at non-pPCI centres in Jakarta. The mean 
‘door-to-device’ time of STEMI patients who were reperfused with pPCI at academic 
centres was shorter than that at non-academic centres. The proportion of STEMI 
patients reperfused with a drug-eluting stent and who received thrombectomy were 
also significantly higher at academic centres compared to non-academic centres. 
Although the clinical outcomes, including in-hospital death, were not significantly 
different between these centres,6 these possible differences in baseline patient 
characteristics limit the generalizability of our findings. 
Another limitation is the unavailability of some clinical information, which hinders us 
from assessing the contraindication of using preventive CV medications. Although 
several studies did not consider a contraindication when assessing guideline 
adherence, our estimation of the level of adherence might underestimate the true 
prevalence, assuming that contraindicated patients were not adequately prescribed 
such medications. As is inherent to observational studies, we cannot rule out the 
possibility of other unmeasured potential confounders that were not included in 
our studies. We may therefore have overestimated the preventive effects of the 
medications on CVD deaths. 
Regarding the qualitative study, we only reached a code saturation with interviews 
of physicians who had relatively homogenous characteristics and came from one city 
in one province in Indonesia. Although this survey is sufficient to support further 
quantitative studies, a larger sample size is needed to attain a meaningful saturation if 
the aim is to gain a deeper understanding of physicians’ prescribing behaviour.9 
One of the main limitations of our studies using the PharmLines Initiative database was 
the relatively small number of participants who met our strict inclusion criteria. This 
might have caused a lack of statistical power to detect smaller differences between 
groups, and hence low precision in the estimates. Finally, a lack of information on 
medications dispensed at hospitals in the IADB.nl database might have led to the 
misclassification of a potential confounder, such as the use of other CV medications, 
and might inadvertently have excluded potential participants who started statins for 




IMPLICATIONS FOR CLINICAL PRACTICE AND 
FURTHER RESEARCH
Our knowledge of the burden of CVD in Indonesia is mostly derived from cross-
sectional studies2,4,10–12 or country report profiles.13,14 Data on the prevalence rates of 
CVD subtypes and risk factors were self-reported.2,4,10–12 In addition to increasing the 
risk of information bias, such data do not permit the calculation of an absolute risk 
estimate of short-term or long-term CVD and their subtypes. Furthermore, death 
registration data were unavailable or unusable due to quality issues.13 Moreover, 
different country reports published by different networks of investigators have 
provided different estimations of the CVD burden. The report by the Institute for 
Health Metrics and Evaluation14 identified the top two causes of most deaths and 
premature deaths as stroke followed by CAD, and this position had not changed 
since 2007. In contrast, the World Health Organization reported CAD to have caused 
more deaths than stroke since 2000.13 This conflicting information might confuse 
policymakers who are responsible for the creation of intervention strategies for CVD 
prevention, as the approaches to the prevention of each disease are not the same. 
Recent studies have analysed data from the hospital-based JAC Registry.5,6,15,16 To our 
knowledge, there are only two well-known registries for acute coronary syndrome 
available in Indonesia and they are designed to manage STEMI patients in Jakarta.17 
The presence of MI registries has been proven to improve the quality of care for 
STEMI patients,18 such as an increase in interhospital referral to a PCI-capable facility 
and the use of pPCI as the reperfusion strategy.16 Such registries are known to serve 
as ‘best practice’ and can improve guideline implementation. These evidence-based 
practices might also be investigated through a sound research methodology. As the 
registries are hospital-based, a study of these registries will provide more evidence on 
the secondary prevention of CVD. Therefore, this area of research should continue, 
and the development of more registries in other regions in Indonesia should be 
encouraged. 
In addition, studies are also needed on the total burden of CVD in Indonesia in 
the general population. To date, we know of only one study that has estimated this 
burden in the general population. The study was a cross-sectional survey, in which 
data were collected through a household visit, interviewing subjects from the general 
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population aged ≥ 40 years in eight purposively selected villages in the second largest 
district of the province of East Java. From the total of 22,093 participants, about 25% 
had a high clinical risk of CVD. This number might under- or over-estimate the real 
prevalence due to the bias of self-reported data.4 Cohort studies are needed to 
obtain more accurate information on the incidence and prevalence of CVD and CV 
risk factors such as diabetes, hypertension and dyslipidaemia.
Findings from cohort studies are needed to guide and strengthen the prevention 
of CVD in primary care. The JKN, which encourages primary health care facilities 
to take a role on the front line of the health system, can follow this up.2,19 This new 
NHIS means CVD-related health care services and medications for the primary and 
secondary prevention of CVD will be subsidized and covered by the JKN.2 We would 
then expect a rise in the utilization of CVD-related health care services, including 
clinical guidelines, as well as the use of preventive CV medications in primary 
health care facilities. This would subsequently lead to a substantial increase in the 
government costs to cover this burden. Therefore, further research on the health 
services is needed to investigate the extent of CVD prevention covered by the JKN 
in primary care, as well as the clinical and economic impacts of the system, with the 
aim of developing and evaluating suitable interventions for the promotion of CVD 
primary prevention in primary care. 
One review of a small number of studies in Indonesia concluded that CVD-related 
health care services were insufficient and unequally distributed, including the supply 
of preventive CV medications, across the entire nation. Between 2015 and 2016, 
it was estimated that there were only 1.5 cardiologists, 0.38 neurologists and 0.4 
endocrinologists per million Indonesians. The total number of Indonesian cardiologists 
was only 365, with most practising in Jakarta, for a population of around 260 million 
in Indonesia.2 For the sake of rough comparison, the cardiologist/inhabitant ratio in 
Indonesia is 35 times less than the ratio in the Netherlands (around 900 cardiologists 
for around 17 million in 2014).20 Another study reflects these findings for Indonesia, 
with the mean number of certified cardiologists reported to be 2.74 per million 
Indonesians, and only 88 hospitals equipped with percutaneous coronary intervention 
(PCI) measures (mean population per PCI centre = 2.7 million) in 2014. In Jakarta, 
however, the mean number of certified cardiologists was 18.9 per million and the 




care by a PCI facility is readily available throughout the country (at least 600 PCI 
procedures per year).20 Moreover, another study revealed there were considerable 
unmet needs for CVD care in the Indonesian population aged ≥ 40 years. Of all 
participants at risk of CVD, only one-third received the treatment needed. However, 
this study did not clearly explain what needs were unmet and what treatment was 
needed.21 The possibility of primary and secondary care overload in the JKN era 
needs to be anticipated and carefully examined. 
Although the JKN will make health care services more accessible to the general 
population, there are other barriers to potential patients even arriving at the access 
point, especially in rural and remote areas in Indonesia. Geographical difficulties and 
out-of-pocket transport expenses have been found to play a significant role in delaying 
timely treatment for acute myocardial infarction and acute stroke,2 which might 
result in death or long-term disabilities. Our findings reflect this, with many STEMI 
patients non-reperfused, while a majority were late presenters. Non-reperfusion itself 
predicted a less optimal prescription of medications to STEMI patients at discharge. 
Since the main therapy for STEMI patients strongly recommended by clinical 
guidelines is acute pPCI in a very timely manner, the reasons behind non-reperfusion 
need to be further explored in quantitative studies to support the development of suitable 
interventions to improve care. 
A qualitative study of community pharmacists (public primary health centres 
[Puskesmas] and pharmacies) in East Java revealed the pharmacists’ perceptions of 
their role in CVD prevention. Not wishing to be confused with physicians, some 
pharmacists perceived that their role was limited to providing medication counselling 
and monitoring medication use only. They also perceived negative attitudes of both 
physicians and patients towards pharmacists playing a greater role, which made them 
hesitant to adopt a more ‘clinical’ role. Pharmacists also had mixed perceptions on 
whether their skills were adequate for this role. There were also several organizational 
barriers, including work overload, lack of incentive and support from the professional 
pharmacy body and government, and the perception that most patients who needed 
CVD-related care went to the secondary health care facilities, with Puskesmas only 
providing basic health care services.22 
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Our findings provided insights into the factors from a physicians’ perspective. In 
addition to non-reperfusion, several baseline patient characteristics, such as older age 
(> 65 years old), non-anterior MI, having a family history of CAD and a TIMI score ≥ 4, 
were independent predictors of receiving less medication at discharge. This suggests 
that physicians could stratify patients based on these baseline characteristics and 
treat them accordingly. However, as the default treatment of STEMI patients is acute 
pPCI, there is no information on risk stratification to guide in-hospital management 
and,23–25 even more, at-discharge therapy.24
Furthermore, the national guidelines in Indonesia adopted international guidelines 
that drew their recommendations from studies in Western populations, with different 
burden and risk factors. This may lead to different opinions on the benefit-risk of 
using guideline-recommended medications among physicians. In our qualitative study, 
physicians had different opinions, for example, on the cut-off of total cholesterol 
required to initiate statin therapy in primary health care settings. Terms such as 
‘guideline’ and ‘risk-assessment’ were not mentioned, unless directly asked, as 
key factors in prescribing statins. The JKN and its platforms were also considered 
when prescribing medication. These findings suggest that prescribing preventive CV 
medications in STEMI patients according to guidelines involves many internal and 
external factors related to the physicians. Thus, the factors that inform a physician’s 
decision and the external barriers in the health system need to be investigated further.
Considering other previous and limited studies, we conclude that CVD prevention 
in Indonesia, especially through the primary care setting, still has a long way to go. In 
the JKN era, when primary health care facilities are readily accessible and covered, 
the size of the population at risk still needs to be accurately estimated. The improved 
use of guidelines, JKN platforms and properly designed research are still required. 
While secondary prevention of CVD needs to be strengthened by continuing the 
use of evidence-based procedures and medications, the reasons behind discordances 
need to be investigated further to identify the risk group who might need different 
approaches.
In the Dutch context, despite many years since the establishment of guidelines on 
prevention of CVD, which strongly advises the use of statins for CVD prevention in the 




and 31% with CVD (secondary prevention) from a Lifelines database study did not 
report receiving lipid-lowering agents (statins and ezetimibe) in accordance with the 
guideline.27 In another study using the PHARMO, a GP database, 67% of high-risk 
Dutch participants with or without CVD were given lipid-lowering agents, which 
were usually statins. In the population treated by statins – on average one daily defined 
dose – 45% did not reach the LDL-c treatment target according to the guidelines. 
Moreover, there was no significant difference in LDL-c target attainment between a 
standard-potency and high-potency group. Due to the nature of the database, the 
actual use of the drug by the patients, which might influence LDL-c target attainment, 
could not be assessed.28 
By using the PharmLines database, which includes the IADB.nl data reporting actual 
dispensing of the medication, we could measure whether factors such as adherence 
might have different effects in different statin dosing groups or different patient risk 
groups. Using this database, we observed differences between men and women in the 
effectiveness of statins on increasing the level of HDL-c. An interaction between sex 
and adherence to statin therapy appeared to have influenced the LDL-c response to 
statins. This finding might prompt further studies with a larger sample size in order to 
identify whether sex-specific guidelines for statin therapy are needed.
CONCLUSIONS
This thesis provided insights into the current challenges to using guideline-
recommended preventive CV medications in high-risk populations in Indonesia and 
the Netherlands. In Indonesia, a substantial percentage of high-risk patients did not 
receive secondary preventive CVD medications recommended by the guidelines. The 
reasons behind this need to be investigated further to be able to design an efficient 
intervention programme. In the Netherlands, differences between the sexes in the 
effect of statins on LDL-c response appeared to be present when adherence to statin 
therapy and the statin dose level were taken into account. These findings suggest that 
a more personalized approach taking sex differences into account is needed, but this 
should be confirmed through larger studies.
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